index - Epidemiology in dermatology and evaluation of therapeutics Accéder directement au contenu

DOCUMENTS

80

 

NOTICES

153

 

 

MOTS CLES

Glucocorticoids Antimicrobials Pharmacovigilance Calcium channel blockers Management Antimicrobial resistance Psoriasis Anti-HCV Direct Acting Antivirals DAA Azathioprine Anxiety Alitretinoin Cardiovascular therapy Cardiomyopathy Vigibase® Anticancer drugs COVID-19 Antibiotics Sacroiliitis Cardio-oncology Burden BTK protein Drug reaction Autoimmunity Care pathway Autoimmune diseases Cancer Antibiotic misuse Axial spondyloarthritis Adverse side effects Dermatology Access to care Angiotensin receptor blockers Intensive care Abus d'antibiotiques Antibiotic resistance Etanercept Acute Myeloid Leukaemia AML Apre-milast Psoriatic arthritis Endocrine toxicity Biomarkers Graft-versus-host disease Cattle Atrial fibrillation Arthritis Accelerometer Ustekinumab Immunotherapy CTLA-4 Quality of life Meta-Analysis Aging ASDAS Atopic dermatitis Treatment Amyloidosis Ethics Arrhythmia Ankylosing spondylitis CSK tyrosine-protein kinase Cardiovascular risk Adalimumab Bacterial rhinosinusitis Biological therapy Epidemiology ArtThese Apremilast Biological Therapy Placebo Stability Biomédicaments Drug survival Biologic drug Prostate cancer Spondyloarthritis Addiction Méta-Analyse Auto-immune hepatitis Sipuleucel-T Infliximab Biologic Case-Control Studies Antimicrobiens Alcohol Immune-related adverse events Albinism Adolescent Biologic therapy Ankylosing Biosimilar Pharmaceuticals Auto-Diagnostic Anxiété Primary adrenal insufficiency Immune checkpoint inhibitors Biologics Angiotensin-converting enzyme inhibitors Pharmacoepidemiology Cardiotoxicity Beta-lactam antibiotics Anti-TNF

 

 

 

Epidemiology in Dermatology and Evaluation of therapeutics , EA 7379

Adresse

Université Paris-Est Créteil Val de Marne (UPEC)

Campus Centre de Créteil
61 Avenue du Général de Gaulle
94010 Créteil Cedex

Courriel

emilie.sbidian@aphp.fr

Site Internet

 

Rattachement(s)

UFR de Santé

Direction

Émilie SBIDIAN

 

Axe(s) de recherche

 


[legende-image]65[/legende-image] Axe 1 : Comment mieux gérer les patients ayant développé des réactins graves aux médicaments, notamment en leur indiquant comment utiliser correctement les agents


[legende-image]65[/legende-image] Axe 2 : Rechercher les facteurs associés aux effets indesirables et à l'efficacité du médicament

 
 

COLLABORATIONS